REC 0545, Recordati’s investigational treatment for maple syrup urine disease (MSUD), a rare genetic metabolic disorder that starts in early infancy, is among the latest products that the European Medicines Agency has begun reviewing for potential pan-EU marketing authorization.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?